290 related articles for article (PubMed ID: 8630379)
1. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Samuel S; Kapelushnik J; Brautbar C; Or R
Blood; 1996 Mar; 87(6):2195-204. PubMed ID: 8630379
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
3. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.
Kapelushnik J; Nagler A; Or R; Naparstek E; Ackerstein A; Samuel S; Morecki S; Nabet C; Slavin S
Bone Marrow Transplant; 1996 Dec; 18(6):1153-6. PubMed ID: 8971387
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes.
Slavin S; Ackerstein A; Morecki S; Gelfand Y; Cividalli G
Bone Marrow Transplant; 2001 Oct; 28(8):795-8. PubMed ID: 11781634
[TBL] [Abstract][Full Text] [Related]
6. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Schaefer UW
Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
[TBL] [Abstract][Full Text] [Related]
7. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
8. Lymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML--a case report.
Lönnqvist B; Brune M; Ljungman P
Bone Marrow Transplant; 1996 Jul; 18(1):241-2. PubMed ID: 8832027
[TBL] [Abstract][Full Text] [Related]
9. Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies.
Park SJ; Min WS; Yang IH; Kim HJ; Min CK; Eom HS; Kim DW; Han CW; Lee JW; Kim CC
Korean J Intern Med; 2000 Dec; 15(3):224-31. PubMed ID: 11242811
[TBL] [Abstract][Full Text] [Related]
10. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
[TBL] [Abstract][Full Text] [Related]
12. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Pawson R; Potter MN; Theocharous P; Lawler M; Garg M; Yin JA; Rezvani K; Craddock C; Rassam S; Prentice HG
Br J Haematol; 2001 Dec; 115(3):622-9. PubMed ID: 11736947
[TBL] [Abstract][Full Text] [Related]
14. Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children.
Parsons SK; Castellino SM; Lehmann LE; Eickhoff CE; Tarbell NJ; Sallan SE; Weinstein HJ; Billett AL
Bone Marrow Transplant; 1996 May; 17(5):763-8. PubMed ID: 8733695
[TBL] [Abstract][Full Text] [Related]
15. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation.
Grigg A; Kannan K; Schwarer AP; Spencer A; Szer J
Intern Med J; 2001; 31(1):15-22. PubMed ID: 11478351
[TBL] [Abstract][Full Text] [Related]
17. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected].
Klingemann HG; Grigg AP; Wilkie-Boyd K; Barnett MJ; Eaves AC; Reece DE; Shepherd JD; Phillips GL
Blood; 1991 Dec; 78(12):3306-11. PubMed ID: 1742491
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
Choi SJ; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Chi HS; Lee KH
Leukemia; 2004 Nov; 18(11):1789-97. PubMed ID: 15385924
[TBL] [Abstract][Full Text] [Related]
19. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
